MIGARD

This brand name is authorized in Estonia, Finland, Lithuania, UK.

Active ingredients

The drug MIGARD contains one active pharmaceutical ingredient (API):

1	Frovatriptan UNII D28J6W18HY - FROVATRIPTAN SUCCINATE
	Frovatriptan is a selective agonist for 5-HT receptors. Frovatriptan is believed to act selectively on extracerebral, intracranial arteries to inhibit the excessive dilatation of these vessels in migraine.
	Read more about Frovatriptan

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
MIGARD Film-coated tablet	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N02CC07	Frovatriptan	N Nervous system → N02 Analgesics → N02C Antimigraine preparations → N02CC Selective serotonin (5HT1) agonists
Discover more medicines within N02CC07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1161537, 1161548, 1161559, 1161560, 1161571, 1161582, 1161593
FI	Lääkealan turvallisuus- ja kehittämiskeskus	019808, 020027, 020053
GB	Medicines & Healthcare Products Regulatory Agency	43642
LT	Valstybinė vaistų kontrolės tarnyba	1016988, 1016989, 1016990, 1016991, 1016992, 1016993